Corline Biomedical (CLBIO.ST) Stock Analysis & AI Equity Report
Corline Biomedical (CLBIO.ST) overview
Corline Biomedical (CLBIO.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, Corline Biomedical reported revenue of SEK 9.8m and operating profit of SEK -23.2m; the year-end share price was 8.78 SEK and market capitalisation was SEK 192m. Corline Biomedical is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Corline Biomedical's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-05. Data will be refreshed during report generation.
About Corline Biomedical
Corline Biomedical develops and sells antithrombotic and anti-inflammatory surface coating solutions for medical devices and regenerative medicine. Its core platform, CHC technology, is used in the CHS coating for device applications and in Renaparin and related products for kidney transplantation, cell therapy, and soft tissue repair. The company also provides coating services and reagent manufacturing.
Generate the Corline Biomedical report
Corline Biomedical is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Corline Biomedical and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.